|
humans |
30 |
|
male |
20 |
|
adult |
17 |
|
female |
17 |
|
hepatocellular carcinoma |
15 |
|
peptidyl-prolyl-isomerase |
15 |
|
pin1 |
15 |
|
middle aged |
14 |
|
β-catenin |
14 |
|
reverse transcriptase polymerase chain reaction |
13 |
|
cell line, tumor |
12 |
|
transfection |
12 |
|
aged |
11 |
|
animals |
11 |
|
beta catenin |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
mice |
11 |
|
mice, nude |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
trans-activators - genetics |
11 |
|
alemtuzumab |
9 |
|
carcinoma, hepatocellular - genetics |
9 |
|
dna, viral - analysis |
9 |
|
epstein barr virus |
9 |
|
follow-up studies |
9 |
|
liver neoplasms - genetics |
9 |
|
treatment outcome |
9 |
|
adolescent |
8 |
|
cytomegalovirus |
8 |
|
retrospective studies |
8 |
|
acute promyelocytic leukemia |
7 |
|
aged, 80 and over |
7 |
|
arsenic trioxide |
7 |
|
beta catenin - genetics |
7 |
|
cell line |
7 |
|
cyclin d1 - genetics |
7 |
|
dna methylation |
7 |
|
gene expression regulation, neoplastic - genetics |
7 |
|
hematopoietic stem cell transplantation |
7 |
|
neoplasm proteins - genetics |
7 |
|
nk/t-cell lymphoma |
7 |
|
pembrolizumab |
7 |
|
peptidylprolyl isomerase - genetics |
7 |
|
phosphorylation |
7 |
|
prophylaxis |
7 |
|
rna interference |
7 |
|
rna, neoplasm - genetics |
7 |
|
transfection - methods |
7 |
|
up-regulation - genetics |
7 |
|
young adult |
7 |
|
amino acid motifs |
6 |
|
asian continental ancestry group |
6 |
|
bcl-x protein - genetics - metabolism |
6 |
|
breakthrough invasive fungal infections |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
carcinoma, hepatocellular - etiology |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
6 |
|
cell proliferation |
6 |
|
cell transformation, neoplastic - genetics - metabolism |
6 |
|
echinocandin |
6 |
|
fatal outcome |
6 |
|
graft versus host disease |
6 |
|
haematopoietic stem cell transplantation |
6 |
|
hematology |
6 |
|
hepatitis b - complications - genetics - metabolism - pathology - virology |
6 |
|
hepatitis b surface antigens - blood - immunology |
6 |
|
hepatitis b virus - genetics - immunology |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
killer cells, natural |
6 |
|
leukaemia |
6 |
|
liver - chemistry - pathology |
6 |
|
liver cirrhosis - etiology |
6 |
|
liver neoplasms - etiology |
6 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
6 |
|
liver neoplasms, experimental - metabolism - pathology - virology |
6 |
|
lung function decline |
6 |
|
peptidylprolyl isomerase - genetics - metabolism |
6 |
|
proline |
6 |
|
protein binding |
6 |
|
proto-oncogene proteins c-myc - genetics - metabolism |
6 |
|
recurrence |
6 |
|
reproducibility of results |
6 |
|
rna, messenger - metabolism |
6 |
|
serine |
6 |
|
trans-activators - genetics - metabolism |
6 |
|
transcription factor rela - genetics - metabolism |
6 |
|
transcription, genetic |
6 |
|
transcriptional activation |
6 |
|
transplantation, heterologous |
6 |
|
up-regulation |
6 |
|
antibodies, monoclonal - administration & dosage |
5 |
|
antibodies, monoclonal, humanized |
5 |
|
antibodies, monoclonal, murine-derived |
5 |
|
antifungal drug |
5 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects - therapeutic use |
5 |
|
asia |
5 |
|
azithromycin |
5 |
|
bone marrow transplantation |
5 |
|
bronchiolitis obliterans syndrome (bos) |
5 |
|
child |
5 |
|
china |
5 |
|
chinese |
5 |
|
dexamethasone - administration & dosage - adverse effects |
5 |
|
diffuse large b cell lymphoma |
5 |
|
disease-free survival |
5 |
|
dlbcl |
5 |
|
dli |
5 |
|
exome sequencing |
5 |
|
fludarabine |
5 |
|
fnd |
5 |
|
genetic mutations |
5 |
|
graft vs host disease - drug therapy - etiology - pathology |
5 |
|
hematologic neoplasms - complications - therapy |
5 |
|
hematopoietic sct (hsct) |
5 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
5 |
|
hodgkin lymphoma |
5 |
|
hsct |
5 |
|
immunophenotyping |
5 |
|
indolent lymphoma |
5 |
|
l-asparaginase |
5 |
|
leukemia, large granular lymphocytic - complications - drug therapy |
5 |
|
leukemia, prolymphocytic, t-cell - drug therapy - ethnology |
5 |
|
liver diseases - drug therapy - etiology |
5 |
|
liver gvhd |
5 |
|
low‐dose |
5 |
|
lymphocyte transfusion - adverse effects |
5 |
|
lymphoma, b-cell - drug therapy - ethnology |
5 |
|
lymphoma, non-hodgkin - drug therapy - ethnology |
5 |
|
lymphoma, t-cell - epidemiology - pathology - therapy |
5 |
|
mature t-cell lymphoma |
5 |
|
mitoxantrone - administration & dosage - adverse effects |
5 |
|
mucosa-associated lymphoid tissue |
5 |
|
myeloma |
5 |
|
nivolumab |
5 |
|
nk-cell lymphoma |
5 |
|
non-gastric marginal zone lymphoma |
5 |
|
post-transplant lymphoproliferative disorders |
5 |
|
prevalence |
5 |
|
prospective studies |
5 |
|
protein-losing enteropathies - drug therapy - etiology |
5 |
|
refractory |
5 |
|
reverse transcriptase polymerase chain reaction - methods |
5 |
|
rituximab |
5 |
|
sex factors |
5 |
|
smile |
5 |
|
splenic marginal zone lymphoma |
5 |
|
survival analysis |
5 |
|
tcga |
5 |
|
the cancer genome atlas |
5 |
|
transplantation, homologous |
5 |
|
vidarabine - administration & dosage - adverse effects - analogs & derivatives |
5 |
|
actins - genetics |
4 |
|
acute myeloid leukemia |
4 |
|
antibodies, monoclonal - administration & dosage - adverse effects |
4 |
|
antibodies, neoplasm - administration & dosage - adverse effects |
4 |
|
antigens, viral - blood |
4 |
|
antineoplastic agents - administration & dosage - adverse effects |
4 |
|
antineoplastic agents - therapeutic use |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
autoimmune diseases - blood - complications - drug therapy - virology |
4 |
|
basal ganglion |
4 |
|
bone marrow cells - drug effects - metabolism |
4 |
|
cancer prognosis |
4 |
|
cancer recurrence |
4 |
|
cancer regression |
4 |
|
cancer risk |
4 |
|
cancer staging |
4 |
|
case report |
4 |
|
chronic lymphocytic leukemia |
4 |
|
clinical article |
4 |
|
clofarabine |
4 |
|
corpus callosum |
4 |
|
cytomegalovirus infections - blood - chemically induced - prevention & control |
4 |
|
cytomegalovirus reactivation |
4 |
|
death-associated protein kinases - genetics - metabolism |
4 |
|
deep vein thrombosis |
4 |
|
dna, viral - blood |
4 |
|
dna, viral - blood - isolation & purification |
4 |
|
epigenesis, genetic - drug effects |
4 |
|
epstein-barr virus dna |
4 |
|
epstein-barr virus infections - complications - drug therapy - pathology |
4 |
|
gene expression |
4 |
|
genetic predisposition to disease |
4 |
|
haploinsufficiency |
4 |
|
hepatitis b - pathology |
4 |
|
hepatitis b virus - genetics - isolation & purification |
4 |
|
herpesvirus 4, human - isolation & purification - physiology |
4 |
|
hodgkin disease - drug therapy - pathology - virology |
4 |
|
immunocompromised host - drug effects |
4 |
|
immunosuppressive agents - administration and dosage |
4 |
|
leukemia |
4 |
|
leukemia, lymphocytic, chronic, b-cell - diagnosis - genetics |
4 |
|
liver - pathology - virology |
4 |
|
living donors |
4 |
|
lymphoma |
4 |
|
lymphoma - blood - complications - drug therapy - virology |
4 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology - virology |
4 |
|
medical sciences |
4 |
|
medicine & public health |
4 |
|
melanoma |
4 |
|
micro-rna |
4 |
|
microrna |
4 |
|
micrornas - genetics - metabolism |
4 |
|
mir-874-3p |
4 |
|
monitoring, physiologic - methods |
4 |
|
monomorphic epitheliotropic intestinal t cell lymphoma |
4 |
|
multiple myeloma - therapy |
4 |
|
myelodysplastic syndromes - genetics - metabolism |
4 |
|
neoplasms, multiple primary |
4 |
|
nonsmall cell lung cancer |
4 |
|
nuclear proteins - biosynthesis - genetics |
4 |
|
oncology |
4 |
|
pad |
4 |
|
pancytopenia - blood - complications - drug therapy - virology |
4 |
|
pd1 |
4 |
|
pdl1 |
4 |
|
pdl2 |
4 |
|
positron emission tomography computed tomography |
4 |
|
positron-emission tomography |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - etiology |
4 |
|
prognosis |
4 |
|
prognostic factors |
4 |
|
promoter regions, genetic - genetics |
4 |
|
relapse |
4 |
|
remission induction |
4 |
|
rna, messenger - genetics |
4 |
|
solid tumors |
4 |
|
staged approach |
4 |
|
tomography, x-ray computed |
4 |
|
tp53 network |
4 |
|
tumor suppressor |
4 |
|
valganciclovir |
4 |
|
virus activation - drug effects |
4 |
|
vtd |
4 |
|
abdominal pain - etiology |
3 |
|
adenine nucleotides - administration & dosage - adverse effects |
3 |
|
allogeneic |
3 |
|
allogeneic haematopoietic stem cell transplantation |
3 |
|
antibodies, monoclonal - therapeutic use |
3 |
|
antibodies, neoplasm - administration & dosage |
3 |
|
antibodies, neoplasm - therapeutic use |
3 |
|
antimetabolites, antineoplastic - administration & dosage - adverse effects |
3 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
3 |
|
arabinonucleosides - administration & dosage - adverse effects |
3 |
|
autologous |
3 |
|
biopsy, needle |
3 |
|
bone marrow - pathology |
3 |
|
bone neoplasms - radiography - secondary |
3 |
|
bortezomib-based induction |
3 |
|
candidiasis - chemically induced - pathology |
3 |
|
cd3 antigen |
3 |
|
cd4 antigen |
3 |
|
cd56 antigen |
3 |
|
cd8 antigen |
3 |
|
chromosomes, human, pair 22 - genetics |
3 |
|
chromosomes, human, pair 9 - genetics |
3 |
|
cohort studies |
3 |
|
cytarabine - administration & dosage - adverse effects |
3 |
|
cytomegalovirus - drug effects |
3 |
|
dexamethasone - administration & dosage |
3 |
|
droplet digital polymerase chain reaction |
3 |
|
drug evaluation |
3 |
|
enteropathy-sssociated t-cell lymphoma - immunology - pathology - physiopathology - therapy |
3 |
|
exanthema - chemically induced - microbiology |
3 |
|
first completion remission |
3 |
|
ganciclovir - administration & dosage - analogs & derivatives |
3 |
|
gastrointestinal neoplasms - immunology - pathology - physiopathology - therapy |
3 |
|
gene expression profiling |
3 |
|
genetic aberrations |
3 |
|
haematopoietic sct |
3 |
|
hbx protein |
3 |
|
hepatitis b virus |
3 |
|
hepatitis c virus |
3 |
|
hong kong - epidemiology |
3 |
|
hyperplasia |
3 |
|
immunosuppression - adverse effects |
3 |
|
immunosuppressive agents |
3 |
|
incidence |
3 |
|
independent of iss |
3 |
|
indolent |
3 |
|
intestinal obstruction - etiology |
3 |
|
intestinal perforation - etiology |
3 |
|
lactate dehydrogenase |
3 |
|
leukemia, large granular lymphocytic - diagnosis - drug therapy - epidemiology |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - blood - drug therapy - genetics - pathology |
3 |
|
leukemia, myeloid - complications - drug therapy |
3 |
|
leukemia, myeloid, acute - drug therapy - prevention & control |
3 |
|
leukemia, t-cell - drug therapy |
3 |
|
liver neoplasms - diagnosis - drug therapy |
3 |
|
lymphoma - classification - pathology - radiography |
3 |
|
lymphoma, b-cell - diagnosis - drug therapy |
3 |
|
lymphoma, large b-cell, diffuse - drug therapy |
3 |
|
lymphoproliferative disorders - complications - drug therapy |
3 |
|
maintenance |
3 |
|
measurable-residual disease |
3 |
|
medical oncology - methods |
3 |
|
mitoxantrone - administration & dosage |
3 |
|
muscular diseases - chemically induced - microbiology |
3 |
|
mycobacterium tuberculosis - pathogenicity |
3 |
|
myelofibrosis |
3 |
|
natural killer cell |
3 |
|
neoplasms, multiple primary - diagnosis - drug therapy |
3 |
|
neutropenia |
3 |
|
neutropenia - drug therapy |
3 |
|
nose neoplasms |
3 |
|
opportunistic infections |
3 |
|
oral |
3 |
|
oral arsenic trioxide maintenance |
3 |
|
piperazines - therapeutic use |
3 |
|
premedication |
3 |
|
prognostic factor |
3 |
|
programmed cell death protein 1 |
3 |
|
protein kinase inhibitors - therapeutic use |
3 |
|
protein-tyrosine kinases - antagonists & inhibitors |
3 |
|
pure red cell aplasia |
3 |
|
pyrimidines - therapeutic use |
3 |
|
reactivation |
3 |
|
rheumatoid arthritis |
3 |
|
rna, messenger - genetics - metabolism |
3 |
|
second complete remission |
3 |
|
signal transduction - genetics |
3 |
|
splenomegaly |
3 |
|
t-cell large granular lymphocyte leukaemia |
3 |
|
t-cell large granular lymphocyte leukemia |
3 |
|
transplant-eligible myeloma |
3 |
|
tuberculosis |
3 |
|
tuberculosis - epidemiology - microbiology - mortality |
3 |
|
vidarabine - administration & dosage - analogs & derivatives |
3 |
|
acute disease |
2 |
|
advanced stage |
2 |
|
algorithms |
2 |
|
anaplastic lymphoma kinase |
2 |
|
anemia, hemolytic, autoimmune - complications - drug therapy - surgery - therapy |
2 |
|
anthrax - diagnosis |
2 |
|
antibodies, monoclonal |
2 |
|
antibodies, monoclonal - adverse effects - therapeutic use |
2 |
|
antibodies, neoplasm - adverse effects - therapeutic use |
2 |
|
antigens, cd - immunology |
2 |
|
antigens, neoplasm - immunology |
2 |
|
antineoplastic combined chemotherapy protocols |
2 |
|
antithyroid agents - therapeutic use |
2 |
|
antiviral agents - therapeutic use |
2 |
|
aquaglyceroporin 9 |
2 |
|
aquaporins - drug effects - genetics - metabolism |
2 |
|
arsenicals - metabolism - pharmacokinetics - pharmacology |
2 |
|
asia-pacific |
2 |
|
asparaginase - administration and dosage |
2 |
|
azacytidine |
2 |
|
azathioprine - therapeutic use |
2 |
|
b-lymphocytes - immunology |
2 |
|
bcl-2 inhibitors |
2 |
|
benzamide |
2 |
|
biomarkers |
2 |
|
blood transfusion |
2 |
|
btk inhibitors |
2 |
|
burden |
2 |
|
cancer |
2 |
|
carbimazole - therapeutic use |
2 |
|
cd56 |
2 |
|
cell proliferation - drug effects |
2 |
|
chidamide |
2 |
|
chinese cll |
2 |
|
chronic lymphocytic leukaemia |
2 |
|
collaboration |
2 |
|
cyclin-dependent kinase |
2 |
|
cytokines |
2 |
|
cytomegalovirus - drug effects - physiology |
2 |
|
cytomegalovirus infections - complications - drug therapy |
2 |
|
demethylating agents |
2 |
|
diagnosis, differential |
2 |
|
diffuse large b-cell lymphoma |
2 |
|
drug resistance |
2 |
|
ebv |
2 |
|
epstein-barr virus |
2 |
|
escherichia coli infections - etiology |
2 |
|
extranodal lymphoma |
2 |
|
extranodal nk/t-cell lymphoma |
2 |
|
ganciclovir - analogs & derivatives - therapeutic use |
2 |
|
glycoproteins - immunology |
2 |
|
graves disease - complications - diagnosis - immunology |
2 |
|
hippocampus |
2 |
|
histone deacetylase inhibitors |
2 |
|
ighv |
2 |
|
immunoglobulins, intravenous - therapeutic use |
2 |
|
immunosuppressive agents - adverse effects - therapeutic use |
2 |
|
isomerization |
2 |
|
italian cll |
2 |
|
k562 cells |
2 |
|
killer cells, natural - pathology |
2 |
|
leukemia, myeloid - metabolism |
2 |
|
leukemia, promyelocytic, acute - cerebrospinal fluid - pathology - radiography |
2 |
|
leukemia, promyelocytic, acute - drug therapy - metabolism |
2 |
|
long-term potentiation |
2 |
|
lymphocytosis |
2 |
|
lymphoma - diagnosis - pathology - therapy |
2 |
|
lymphoma - immunology - pathology |
2 |
|
lymphoma, extranodal nk-t-cell |
2 |
|
lymphoma, extranodal nk-t-cell - diagnosis - drug therapy - genetics - pathology |
2 |
|
lymphoma, follicular |
2 |
|
lymphoma, t-cell - diagnosis - pathology - therapy |
2 |
|
lymphoma, t-cell, cutaneous - complications - diagnosis |
2 |
|
lymphomas |
2 |
|
magnetic resonance imaging |
2 |
|
malignant lymphomas |
2 |
|
mature t cell |
2 |
|
microenvironment |
2 |
|
nasal |
2 |
|
nasal lymphoma |
2 |
|
nk/t-cell lymphomas |
2 |
|
non-nasal |
2 |
|
outcome |
2 |
|
oxides - metabolism - pharmacokinetics - pharmacology |
2 |
|
peripheral t-cell lymphoma |
2 |
|
peritonitis - etiology |
2 |
|
pet/ct |
2 |
|
point mutation |
2 |
|
prednisolone - therapeutic use |
2 |
|
prednisone |
2 |
|
rhoa |
2 |
|
sensitivity and specificity |
2 |
|
sepsis - etiology |
2 |
|
skin diseases, bacterial - diagnosis |
2 |
|
skin neoplasms - immunology - pathology |
2 |
|
splenectomy |
2 |
|
status quo |
2 |
|
stereotyped receptors |
2 |
|
subarachnoid hemorrhage - diagnosis |
2 |
|
synaptic plasticity |
2 |
|
t-cell lymphomas |
2 |
|
t-lymphocytes - immunology |
2 |
|
thrombocytopenia - drug therapy - etiology |
2 |
|
treatment |
2 |
|
tretinoin - pharmacology |
2 |
|
up-regulation - drug effects |
2 |
|
ventriculostomy |
2 |
|
vincristine |
2 |
|
viremia - complications - drug therapy |
2 |
|
adaptor proteins, signal transducing |
1 |
|
allogeneic hematopoietic cell transplantation |
1 |
|
amino acid sequence |
1 |
|
animals, newborn |
1 |
|
antibodies - chemistry - genetics - immunology |
1 |
|
antibody affinity |
1 |
|
antibody specificity - immunology |
1 |
|
antigen-antibody reactions |
1 |
|
antigen-antibody reactions - immunology |
1 |
|
apoptosis |
1 |
|
autologous hematopoietic cell transplantation |
1 |
|
bacteriophages - genetics |
1 |
|
binding sites, antibody - immunology |
1 |
|
blotting, western |
1 |
|
cdkn1b |
1 |
|
cell cycle |
1 |
|
cells, cultured |
1 |
|
central nervous system - embryology - pathology - physiology |
1 |
|
checkpoint |
1 |
|
chloramphenicol o-acetyltransferase |
1 |
|
cho cells |
1 |
|
chromosomal translocation |
1 |
|
chromosomal translocations |
1 |
|
chromosome mapping |
1 |
|
chromosomes, human, pair 1 |
1 |
|
cloning, molecular - methods |
1 |
|
combined modality therapy |
1 |
|
cricetinae |
1 |
|
cytogenetics |
1 |
|
disease models, animal |
1 |
|
disulfides - metabolism |
1 |
|
dna-binding proteins - genetics |
1 |
|
dna-binding proteins - genetics - metabolism |
1 |
|
drug delivery systems - methods |
1 |
|
embryonic and fetal development |
1 |
|
epitopes |
1 |
|
exons - genetics |
1 |
|
functional genomics |
1 |
|
fusion proteins, bcr-abl - genetics - immunology |
1 |
|
gene targeting |
1 |
|
gene therapy |
1 |
|
genes, reporter |
1 |
|
genomic library |
1 |
|
genotype |
1 |
|
guidelines as topic |
1 |
|
hepatocarcinogenes |
1 |
|
hepatocarcinogenesis |
1 |
|
homeodomain proteins - genetics |
1 |
|
homeodomain proteins - genetics - metabolism |
1 |
|
immunoglobulin fab fragments - chemistry - genetics - immunology |
1 |
|
immunoglobulin fragments - genetics - isolation & purification |
1 |
|
immunoglobulin variable region - chemistry - genetics - immunology |
1 |
|
immunoglobulin variable region - genetics |
1 |
|
immunomodulatory agents |
1 |
|
in situ hybridization, fluorescence |
1 |
|
inhibitor |
1 |
|
intrabodies |
1 |
|
intracellular fluid - immunology |
1 |
|
introns - genetics |
1 |
|
jak2 |
1 |
|
lim domain proteins |
1 |
|
lymph nodes |
1 |
|
lymphoid |
1 |
|
mammals |
1 |
|
men syndrome, developmental delay |
1 |
|
metalloproteins - genetics |
1 |
|
mice - genetics |
1 |
|
mice, inbred c57bl |
1 |
|
models, immunological |
1 |
|
molecular sequence data |
1 |
|
morphogenesis |
1 |
|
muridae |
1 |
|
mutation |
1 |
|
myeloproliferative neoplasm |
1 |
|
neoplasms - therapy |
1 |
|
nk/t cell lymphomas |
1 |
|
nuclear proteins |
1 |
|
oncogene proteins |
1 |
|
oncogene proteins - genetics - metabolism |
1 |
|
peptide library |
1 |
|
prevention and control |
1 |
|
protein-tyrosine kinases |
1 |
|
proto-oncogene proteins |
1 |
|
proto-oncogene proteins - genetics - immunology |
1 |
|
proto-oncogene proteins c-abl - genetics - immunology |
1 |
|
proto-oncogene proteins c-bcr |
1 |
|
recombinant proteins - chemistry - genetics - immunology |
1 |
|
saccharomyces cerevisiae - immunology |
1 |
|
scfv |
1 |
|
sequence alignment |
1 |
|
single-chain fv |
1 |
|
t cell lymphomas |
1 |
|
therapy |
1 |
|
transcription factors - genetics |
1 |
|
transcription factors - genetics - metabolism |
1 |
|
transformation, genetic |
1 |
|
translocation, genetic - genetics |
1 |
|
two-hybrid system techniques |
1 |
|
venous thromboembolism |
1 |
